Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation

Bharat Book Bureau provides the report, on “Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation”. In this report main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. https://www.bharatbook.com/healthcare-market-research-reports-201860/frontier-pharma-parkinson-disease-identifying-commercializing1.html

17th March, 2016- Mumbai, India: Bharatbook.com announces a report on “Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation”. This Report accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.

Summary

Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients.

The current market offers a number of anti-PD treatment options which provide symptomatic relief. Levodopa is currently the gold standard therapy, with other drug classes including dopamine agonists and Monoamine Oxidase B (MAO-B) inhibitors also used to treat early and advanced cases. With no current treatment showing effectiveness in delaying the course of the disease, PD remains incurable. The high unmet need for a disease-modifying therapy is reflected in the pipeline, where a high proportion of early-stage first-in-class programs target the potential pathogenic mechanisms underlying neurodegeneration.

Scope

PD is a crowded market with many neuromodulatory drug classes available. However, a disease-modifying therapy with neuroprotective effects is yet to be...